Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-05
2011-07-05
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C530S387100
Reexamination Certificate
active
07973019
ABSTRACT:
The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
REFERENCES:
patent: 5354844 (1994-10-01), Beug et al.
patent: 5670151 (1997-09-01), Larrick et al.
patent: 5840867 (1998-11-01), Toole et al.
patent: 6001648 (1999-12-01), McCall et al.
patent: 6207388 (2001-03-01), Grossman
patent: 6225058 (2001-05-01), Munishkin et al.
patent: 6372250 (2002-04-01), Pardridge
patent: 6632671 (2003-10-01), Unger
patent: 2002/0001810 (2002-01-01), Farrell
patent: 2006/0014172 (2006-01-01), Muller et al.
patent: 2006/0040882 (2006-02-01), Chen et al.
patent: 2006/0166919 (2006-07-01), Shepard et al.
patent: 2006/0172961 (2006-08-01), Clark et al.
patent: 2006/0172963 (2006-08-01), Shepard et al.
patent: 2006/0172965 (2006-08-01), Shepard et al.
patent: 2006/0210527 (2006-09-01), Davis
patent: 2006/0223773 (2006-10-01), Clark et al.
patent: 2006/0286073 (2006-12-01), Tolentino et al.
patent: 2007/0149473 (2007-06-01), Chatterton et al.
patent: 2007/0155690 (2007-07-01), Chatterton et al.
patent: 2007/0287681 (2007-12-01), Jeong et al.
patent: 2009/0087494 (2009-04-01), Kompella et al.
patent: 2009/0247604 (2009-10-01), Tang et al.
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Bora, et al.; “Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of Factor B and Factor H1”; Journal of Immunology; vol. 177; pp. 1872-1878; 2006.
Campochiaro; “Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders”; Gene Therapy; vol. 13; pp. 559-562; 2006.
Fire, et al.; “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans”; Letters to Nature; Nature; vol. 391; pp. 806-811; Feb. 19, 1998.
Wadia, et al.; “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis”; Technical Reports; Nature Medicine; vol. 10; No. 3; pp. 310-315; Mar. 2004.
Song, et al.; “Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors”; Nature Biotechnology; vol. 23; No. 6; pp. 709-717; Jun. 2005.
Qian, et al.; “Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway”; Pharmacological Reviews; vol. 54; No. 4; pp. 561-587; 2002.
Liu, et al.; “Structural reorganization of the transferring C-lobe and transferrin receptor upon complex formation: The C-Lobe binds to the receptor helical domain”; Biochemistry; vol. 42; pp. 12447-12454; 2003.
Hu-Lieskovan, et al.; “Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interferring RNA inhibits tumor growth in a murine model of metastatic ewing's sarcoma”; Cancer Research; vol. 65; No. 19; pp. 8984-8992; Oct. 1, 2005.
Chu, et al.; “Aptamer mediated siRNA delivery”; Nucleic Acids Research; vol. 34; No. 10; pp. e73; 2006.
Callens, et al.; “Recent advances in adult t-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody”; Leukemia; vol. 22; pp. 42-48; 2008.
Kumar, et al.; “Transvascular delivery of small interfering RNA to the central nervous system”; Nature; vol. 448; pp. 39-43; Jul. 5, 2007.
Chatterton Jon E.
Clark Abbot F.
Alcon Research, Ltd.
Bowman Amy
Derry Jason J.
LandOfFree
Transferrin/transferrin receptor-mediated siRNA delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transferrin/transferrin receptor-mediated siRNA delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transferrin/transferrin receptor-mediated siRNA delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738102